The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study

Background. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-in...

Full description

Bibliographic Details
Main Authors: Orianne Villard, David Morquin, Nicolas Molinari, Isabelle Raingeard, Nicolas Nagot, Jean-Paul Cristol, Boris Jung, Camille Roubille, Vincent Foulongne, Pierre Fesler, Sylvain Lamure, Patrice Taourel, Amadou Konate, Alexandre Thibault Jacques Maria, Alain Makinson, Ivan Bertchansky, Romaric Larcher, Kada Klouche, Vincent Le Moing, Eric Renard, Philippe Guilpain
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/9/7/2315
id doaj-2c04eff6a90d477ba798521cc4d333fe
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Orianne Villard
David Morquin
Nicolas Molinari
Isabelle Raingeard
Nicolas Nagot
Jean-Paul Cristol
Boris Jung
Camille Roubille
Vincent Foulongne
Pierre Fesler
Sylvain Lamure
Patrice Taourel
Amadou Konate
Alexandre Thibault Jacques Maria
Alain Makinson
Ivan Bertchansky
Romaric Larcher
Kada Klouche
Vincent Le Moing
Eric Renard
Philippe Guilpain
spellingShingle Orianne Villard
David Morquin
Nicolas Molinari
Isabelle Raingeard
Nicolas Nagot
Jean-Paul Cristol
Boris Jung
Camille Roubille
Vincent Foulongne
Pierre Fesler
Sylvain Lamure
Patrice Taourel
Amadou Konate
Alexandre Thibault Jacques Maria
Alain Makinson
Ivan Bertchansky
Romaric Larcher
Kada Klouche
Vincent Le Moing
Eric Renard
Philippe Guilpain
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
Journal of Clinical Medicine
Covid-19
renin angiotensin aldosterone system
inflammation
endocrine
severity
author_facet Orianne Villard
David Morquin
Nicolas Molinari
Isabelle Raingeard
Nicolas Nagot
Jean-Paul Cristol
Boris Jung
Camille Roubille
Vincent Foulongne
Pierre Fesler
Sylvain Lamure
Patrice Taourel
Amadou Konate
Alexandre Thibault Jacques Maria
Alain Makinson
Ivan Bertchansky
Romaric Larcher
Kada Klouche
Vincent Le Moing
Eric Renard
Philippe Guilpain
author_sort Orianne Villard
title The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
title_short The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
title_full The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
title_fullStr The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
title_full_unstemmed The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
title_sort plasmatic aldosterone and c-reactive protein levels, and the severity of covid-19: the dyhor-19 study
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2020-07-01
description Background. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. Methods. Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. Disease severity was assessed using a seven-category ordinal scale. Primary outcome of interest was the severity of patients’ clinical courses. Results. Forty-four patients were included. At inclusion, 12 patients had mild clinical status, 25 moderate clinical status and 7 severe clinical status. In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (<i>p</i> < 0.01 and <i>p </i>=<i> </i>0.03, respectively). In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Conclusions. Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19. Our findings may open new perspectives in the understanding of the possible role of RAAS for Covid-19 outcome.
topic Covid-19
renin angiotensin aldosterone system
inflammation
endocrine
severity
url https://www.mdpi.com/2077-0383/9/7/2315
work_keys_str_mv AT oriannevillard theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT davidmorquin theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT nicolasmolinari theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT isabelleraingeard theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT nicolasnagot theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT jeanpaulcristol theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT borisjung theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT camilleroubille theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT vincentfoulongne theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT pierrefesler theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT sylvainlamure theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT patricetaourel theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT amadoukonate theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT alexandrethibaultjacquesmaria theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT alainmakinson theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT ivanbertchansky theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT romariclarcher theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT kadaklouche theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT vincentlemoing theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT ericrenard theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT philippeguilpain theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT oriannevillard plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT davidmorquin plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT nicolasmolinari plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT isabelleraingeard plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT nicolasnagot plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT jeanpaulcristol plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT borisjung plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT camilleroubille plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT vincentfoulongne plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT pierrefesler plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT sylvainlamure plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT patricetaourel plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT amadoukonate plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT alexandrethibaultjacquesmaria plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT alainmakinson plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT ivanbertchansky plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT romariclarcher plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT kadaklouche plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT vincentlemoing plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT ericrenard plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
AT philippeguilpain plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study
_version_ 1724671060447592448
spelling doaj-2c04eff6a90d477ba798521cc4d333fe2020-11-25T03:07:21ZengMDPI AGJournal of Clinical Medicine2077-03832020-07-0192315231510.3390/jcm9072315The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 StudyOrianne Villard0David Morquin1Nicolas Molinari2Isabelle Raingeard3Nicolas Nagot4Jean-Paul Cristol5Boris Jung6Camille Roubille7Vincent Foulongne8Pierre Fesler9Sylvain Lamure10Patrice Taourel11Amadou Konate12Alexandre Thibault Jacques Maria13Alain Makinson14Ivan Bertchansky15Romaric Larcher16Kada Klouche17Vincent Le Moing18Eric Renard19Philippe Guilpain20Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Endocrinology, Diabetes, Nutrition, and INSERM 1411 Clinical Investigation Centre, Montpellier University Hospital, INSERM, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceLaboratory of Virology, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Internal Medicine—Multi-organ Diseases, local referral center for auto-immune diseases, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Internal Medicine—Multi-organ Diseases, local referral center for auto-immune diseases, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceBackground. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. Methods. Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. Disease severity was assessed using a seven-category ordinal scale. Primary outcome of interest was the severity of patients’ clinical courses. Results. Forty-four patients were included. At inclusion, 12 patients had mild clinical status, 25 moderate clinical status and 7 severe clinical status. In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (<i>p</i> < 0.01 and <i>p </i>=<i> </i>0.03, respectively). In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Conclusions. Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19. Our findings may open new perspectives in the understanding of the possible role of RAAS for Covid-19 outcome.https://www.mdpi.com/2077-0383/9/7/2315Covid-19renin angiotensin aldosterone systeminflammationendocrineseverity